Overall, this AuNCs-based nanocarrier with the anti-PDL1 as a platform to produce the TAAs and control the AP3 release for stimulating DCs maturation, lead to the activation of T cell and specific targeting of the tumor cells to create an immunogenic TME. Here, CD274 is linked to neoplasm.